READ MOREAstraZeneca said it remained on track for a promised return to sales growth in 2018.
Its latest arrivals - Imfinzi for cancer and Fasenra for severe asthma - both sold well and total product sales in the three months rose a modest 3 percent, helped by a weaker dollar.
Total revenue, however, was down 4 percent at $5.18 billion, due to investment in new drug launches and a lack of divestments compared with a year earlier. Core earnings per share, which exclude some items, slumped 51 percent to 48 cents. ■